This HTML5 document contains 71 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n20http://www.cynapsus.ca/
n9https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
schemahttp://schema.org/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n14http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
n15http://
n12http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
provhttp://www.w3.org/ns/prov#
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
xsdhhttp://www.w3.org/2001/XMLSchema#
n19https://web.archive.org/web/20110706165915/http:/www.biofinance.ca/EarlyPhase/
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Cynapsus_Therapeutics
rdf:type
yago:Group100031264 yago:Institution108053576 yago:DrugCompany108002578 dbo:Agent n14:SocialPerson owl:Thing n14:Agent wikidata:Q24229398 yago:SocialGroup107950920 yago:WikicatPharmaceuticalCompaniesOfCanada yago:Organization108008335 yago:WikicatCompaniesListedOnTheTSXVentureExchange yago:Abstraction100002137 dbo:Organisation yago:Company108058098 yago:YagoPermanentlyLocatedEntity yago:YagoLegalActor yago:YagoLegalActorGeo dbo:Company wikidata:Q4830453 yago:WikicatCompaniesBasedInToronto wikidata:Q43229 schema:Organization
rdfs:label
Cynapsus Therapeutics
rdfs:comment
Cynapsus Therapeutics Inc. is a specialty pharmaceutical company developing a drug to treat the motor symptoms of Parkinson's disease. Based in Toronto, Ontario, Canada. Formerly named Cannasat Therapeutics they changed their name to Cynapsus Therapeutics in 2010. In September 2016, Sunovion (a subsidiary of Dainippon Sumitomo Pharma) announced it would acquire Cynapsus Therapeutics for approximately $624 million.
foaf:name
Cynapsus Therapeutics Inc.
foaf:homepage
n15:www.sunovion.com
dbp:name
Cynapsus Therapeutics Inc.
foaf:depiction
n12:Cynapsus_Therapeutics_logo.jpg
dbo:location
dbr:Massachusetts dbr:Marlborough,_Massachusetts
dcterms:subject
dbc:Pharmaceutical_companies_of_Canada dbc:Companies_formerly_listed_on_the_Toronto_Stock_Exchange dbc:Companies_based_in_Toronto
dbo:wikiPageID
20421670
dbo:wikiPageRevisionID
1041942769
dbo:wikiPageWikiLink
dbr:Dainippon_Sumitomo_Pharma dbc:Pharmaceutical_companies_of_Canada dbr:Subsidiary dbr:Massachusetts dbr:Sunovion dbc:Companies_formerly_listed_on_the_Toronto_Stock_Exchange dbr:Pharmacology dbr:Toronto dbr:Marlborough,_Massachusetts dbc:Companies_based_in_Toronto
dbo:wikiPageExternalLink
n19:CannasatTherapeutics n20: n15:www.sunovion.com
owl:sameAs
freebase:m.04z_b4x n9:4ibSq wikidata:Q5199886 yago-res:Cynapsus_Therapeutics
dbp:wikiPageUsesTemplate
dbt:Infobox_company dbt:Reflist
dbo:thumbnail
n12:Cynapsus_Therapeutics_logo.jpg?width=300
dbp:foundation
1984
dbp:homepage
n15:www.sunovion.com
dbp:industry
dbr:Pharmacology
dbp:location
Marlborough, Massachusetts, United States
dbp:logo
File:Cynapsus Therapeutics logo.jpg
dbp:parent
dbr:Sunovion
dbp:type
dbr:Subsidiary
dbo:abstract
Cynapsus Therapeutics Inc. is a specialty pharmaceutical company developing a drug to treat the motor symptoms of Parkinson's disease. Based in Toronto, Ontario, Canada. Formerly named Cannasat Therapeutics they changed their name to Cynapsus Therapeutics in 2010. In September 2016, Sunovion (a subsidiary of Dainippon Sumitomo Pharma) announced it would acquire Cynapsus Therapeutics for approximately $624 million.
prov:wasDerivedFrom
wikipedia-en:Cynapsus_Therapeutics?oldid=1041942769&ns=0
dbo:wikiPageLength
4064
dbo:foundingYear
1984-01-01
dbo:industry
dbr:Pharmacology
dbo:parentCompany
dbr:Sunovion
dbo:type
dbr:Subsidiary
foaf:isPrimaryTopicOf
wikipedia-en:Cynapsus_Therapeutics